Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients: Effect of timing and immunologic parameters()

Rituximab (RTX), an important therapeutic option for patients with rheumatic diseases, has been shown to reduce immune responses to various vaccines. We asked whether following SARS-CoV-2 vaccination, response rates in RTX treated patients are reduced and whether specific patient characteristics inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Magliulo, Daniel, Wade, Stefanie D., Kyttaris, Vasileios C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627008/
https://www.ncbi.nlm.nih.gov/pubmed/34848357
http://dx.doi.org/10.1016/j.clim.2021.108897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627008/
https://www.ncbi.nlm.nih.gov/pubmed/34848357
http://dx.doi.org/10.1016/j.clim.2021.108897

Ejemplares similares